Key points

In infants

• The mandatory meningococcal ACWY vaccination, implemented on January 1, 2025, for infants following an increase in cases of invasive meningococcal infections of types W and Y, has resulted in high vaccination coverage, with nearly 88% of infants born in 2025 having received the first dose of the meningococcal ACWY vaccine. This vaccination coverage is similar to that estimated in 2024 for meningococcal C.
• Among children born in 2024—that is, before the replacement of the meningococcal C vaccine with the ACWY vaccine—82% had received at least one dose of the tetravalent ACWY meningococcal vaccine by the age of 21 months. It should be noted that vaccination started with a monovalent C vaccine before January 1, 2025, in infants must be continued with a tetravalent ACWY vaccine.
• In 2025, the year the mandatory meningococcal B vaccination for infants up to age 2 was implemented, vaccination coverage against these infections increased significantly, with 63% of infants born in 2024 (aged 21 months) up to date on their vaccinations (an increase of 13 percentage points compared to 2024).
• Vaccination coverage for other mandatory infant vaccinations is generally high, with levels close to the 95% target set by the World Health Organization (WHO).
• Nevertheless, given the resurgence of measles virus circulation in France since 2024, it is important to note that vaccination coverage for the two doses of the measles, mumps, and rubella (MMR) vaccine must exceed this target to interrupt the virus’s circulation, which can lead to deaths among vulnerable individuals. Verifying and updating this vaccination status is essential for both children and young adults.

Among adolescents and young adults

• Given the potential severity and increased frequency of invasive meningococcal infections during adolescence, vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults. In 2025, only 13% of 11- to 14-year-olds and 5% of 15- to 24-year-olds had received a dose of this vaccine. Vaccination against meningococcal ACWY must be stepped up in this age group.
  Incorporating this vaccination into campaigns conducted in middle schools starting in 2026 will help strengthen young people’s protection against these infections. Efforts to improve vaccination coverage must continue in order to achieve herd immunity and reduce the circulation of meningococci in other age groups.
• Vaccination coverage against human papillomavirus (HPV) infections continues to increase, with 42% of 16-year-old girls and 24% of 16-year-old boys having received a full vaccination series. The gap in vaccination coverage between girls and boys continues to narrow.
• This progress is encouraging, but vaccination coverage remains insufficient to reduce the incidence of cancers linked to these infections. The national target set by the 10-year cancer control strategy is 80% for both girls and boys by 2030. Efforts must also continue to accelerate the uptake of HPV vaccination to achieve this goal by leveraging vaccination campaigns in middle schools and reinforcing messages about the importance of vaccinating boys. Vaccinating boys is just as essential as vaccinating girls: it contributes to equitable and sustainable protection.

Vaccination Uptake

According to the 2024 Santé publique France Barometer in Provence-Alpes-Côte d’Azur, even though 78% of adults aged 18 to 79 reported being very or somewhat in favor of vaccination, the region had one of the lowest vaccination uptake rates in France and showed no real progress compared to the estimated level in 2021.

Among young people, however, the uptake rate was higher, with 82% of those aged 18–25 stating they were very or somewhat in favor of vaccination in general.